HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...

In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE). IL-2 stands for interleukin-2 – a ...

Researchers at Peking Union Medical College Hospital have mapped out why pairing two well-known cancer drugs can turn “sleepy” immune cells back into tumor killers. In a new Perspective published ...

Low dose interleukin 2 is being tested as an immunomodulatory approach in neurodegenerative diseases. It increases the number and activity of regulatory T cells (Tregs) that suppress inflammation. At ...

Dr. Randi Isaacs' upcoming presentation at the KidneyCAN 7th Annual Kidney Cancer Research Summit highlights Werewolf's innovation in conditionally activated therapeutics, which could enhance ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today presented positive translational results from the Phase 1a dose escalation portion of a Phase ...

AIDS-Related Kaposi’s Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and ...

Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further ...